
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8569655/publications.pdf Version: 2024-02-01



Δέτρα Βαιι

#	Article	IF	CITATIONS
1	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. British Journal of Dermatology, 2016, 175, 561-571.	1.5	144
2	Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 65-71.	2.8	108
3	EQ-5D in Central and Eastern Europe: 2000–2015. Quality of Life Research, 2016, 25, 2693-2710.	3.1	103
4	Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Review of Clinical Immunology, 2015, 11, 43-52.	3.0	83
5	Health promotion targeting older people. BMC Health Services Research, 2016, 16, 345.	2.2	66
6	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Advances in Therapy, 2017, 34, 1128-1144.	2.9	64
7	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. European Journal of Health Economics, 2019, 20, 57-69.	2.8	49
8	Informal payments for healthcare services and shortâ€ŧerm effects of the introduction of visit fee on these payments in Hungary. International Journal of Health Planning and Management, 2012, 27, 63-79.	1.7	48
9	User fees for public health care services in Hungary: Expectations, experience, and acceptability from the perspectives of different stakeholders. Health Policy, 2011, 102, 255-262.	3.0	44
10	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 1-7.	1.4	44
11	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. European Journal of Health Economics, 2016, 17, 89-98.	2.8	41
12	Changes in Equity in Out-of-pocket Payments during the Period of Health Care Reforms: Evidence from Hungary. International Journal for Equity in Health, 2012, 11, 36.	3.5	36
13	Access to biologicals in Crohn's disease in ten European countries. World Journal of Gastroenterology, 2017, 23, 6294.	3.3	35
14	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Current Medicinal Chemistry, 2019, 26, 259-269.	2.4	34
15	Exploring consumers' attitudes towards informal patient payments using the combined method of cluster and multinomial regression analysis - the case of Hungary. BMC Health Services Research, 2013, 13, 62.	2.2	33
16	Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. PLoS ONE, 2014, 9, e107704.	2.5	31
17	Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. European Journal of Health Economics, 2016, 17, 99-108.	2.8	31
18	Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists. Scandinavian Journal of Gastroenterology, 2016, 51, 22-27.	1.5	30

#	Article	IF	CITATIONS
19	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. Pain, 2017, 158, 2259-2267.	4.2	30
20	Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. European Journal of Health Economics, 2014, 15, 45-52.	2.8	27
21	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. European Journal of Health Economics, 2014, 15, 53-64.	2.8	26
22	Informal cash payments for birth in Hungary: Are women paying to secure a known provider, respect, or quality of care?. Social Science and Medicine, 2017, 189, 86-95.	3.8	25
23	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. British Journal of Dermatology, 2015, 173, 1076-1080.	1.5	24
24	Cost-of-illness studies in nine Central and Eastern European countries. European Journal of Health Economics, 2019, 20, 155-172.	2.8	23
25	Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. European Journal of Health Economics, 2014, 15, 101-109.	2.8	22
26	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 597-606.	1.4	22
27	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. European Journal of Health Economics, 2019, 20, 5-16.	2.8	22
28	Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Annals of the Rheumatic Diseases, 2016, 75, 942-943.	0.9	21
29	Costâ€effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. United European Gastroenterology Journal, 2018, 6, 310-321.	3.8	20
30	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. Kardiologia Polska, 2018, 76, 860-870.	0.6	19
31	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. Pathology and Oncology Research, 2015, 21, 619-627.	1.9	17
32	Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. BMC Geriatrics, 2017, 17, 233.	2.7	17
33	Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey. European Journal of Health Economics, 2019, 20, 71-78.	2.8	17
34	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. European Journal of Health Economics, 2019, 20, 119-132.	2.8	17
35	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. Journal of Medical Internet Research, 2020, 22, e19013.	4.3	17
36	Discrepancies between the Dermatology Life Quality Index and utility scores. Quality of Life Research, 2016, 25, 1687-1696.	3.1	16

#	Article	IF	CITATIONS
37	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. British Journal of Dermatology, 2016, 175, 593-599.	1.5	15
38	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 139-147.	1.9	15
39	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 27-34.	2.8	14
40	The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study. European Journal of Health Economics, 2014, 15, 853-867.	2.8	13
41	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. Quality of Life Research, 2020, 29, 2863-2874.	3.1	13
42	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. European Journal of Health Economics, 2014, 15, 73-82.	2.8	12
43	Adaptation or recovery after health shocks? Evidence using subjective and objective health measures. Health Economics (United Kingdom), 2018, 27, 850-864.	1.7	12
44	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. European Journal of Health Economics, 2019, 20, 141-154.	2.8	12
45	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues, 2016, 10, 85-90.	1.2	11
46	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. European Journal of Health Economics, 2019, 20, 17-30.	2.8	11
47	Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries. European Journal of Health Economics, 2016, 17, 791-799.	2.8	10
48	Patient experiences with outpatient care in Hungary: results of an online population survey. European Journal of Health Economics, 2019, 20, 79-90.	2.8	10
49	Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries. Society and Economy, 2012, 34, 221-240.	0.3	9
50	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. Rheumatology International, 2017, 37, 1957-1977.	3.0	9
51	Assessing quality of maternity care in Hungary: expert validation and testing of the mother-centered prenatal care (MCPC) survey instrument. Reproductive Health, 2017, 14, 152.	3.1	9
52	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. European Journal of Health Economics, 2019, 20, 109-117.	2.8	8
53	Preferences of Hungarian consumers for quality, access and price attributes of health care services — result of a discrete choice experiment. Society and Economy, 2012, 34, 293-311.	0.3	7
54	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQIâ€Relevant (DLQIâ€R) scoring. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e484-e486.	2.4	7

#	Article	IF	CITATIONS
55	Examining obstetric interventions and respectful maternity care in Hungary: Do informal payments for continuity of care link to quality?. Birth, 2021, 48, 309-318.	2.2	7
56	Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. Pharmacoeconomics, 2020, 38, 633-643.	3.3	6
57	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. Quality of Life Research, 2021, 30, 629-641.	3.1	6
58	Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. Value in Health, 2021, 24, 1845-1852.	0.3	6
59	Long-term costs and survival of prostate cancer: a population-based study. International Urology and Nephrology, 2017, 49, 1707-1714.	1.4	5
60	Does the Implementation of Official User Charges Help to Eradicate Informal Payments – Lessons to be Learnt from the Hungarian Experience. Frontiers in Public Health, 2015, 3, 181.	2.7	4
61	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). Applied Research in Quality of Life, 2017, 12, 409-424.	2.4	4
62	Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample. PLoS ONE, 2020, 15, e0235165.	2.5	4
63	Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50–70: a cross-sectional study on a representative sample of the Hungarian general population. European Journal of Health Economics, 2021, 22, 1453-1466.	2.8	4
64	Understanding the use of patient-reported data by health care insurers: A scoping review. PLoS ONE, 2020, 15, e0244546.	2.5	4
65	Comparing self-perceived and estimated fracture risk by FRAX® of women with osteoporosis. Archives of Osteoporosis, 2017, 12, 4.	2.4	3
66	Acceptable health and ageing: results of a cross-sectional study from Hungary. Health and Quality of Life Outcomes, 2020, 18, 346.	2.4	3
67	Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. International Journal of Environmental Research and Public Health, 2021, 18, 2213.	2.6	3
68	PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY. Value in Health, 2019, 22, S794.	0.3	2
69	Patient experiences in a public primary health care clinic: A South African case study. Society and Economy, 2020, 42, 333-347.	0.3	2
70	The impact of the recession on health care expenditure — How does the Czech Republic, Hungary, Poland and Slovakia compare to other OECD countries?. Society and Economy, 2015, 37, 73-88.	0.3	1
71	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. Musculoskeletal Science and Practice, 2021, 55, 102420.	1.3	1
72	Long-term care financing in Europe: An overview. Zdrowie Publiczne I ZarzÄdzanie, 2019, 17, 131-145.	0.4	0

#	Article	IF	CITATIONS
73	Title is missing!. , 2020, 15, e0235165.		0
74	Title is missing!. , 2020, 15, e0235165.		0
75	Title is missing!. , 2020, 15, e0235165.		0
76	Title is missing!. , 2020, 15, e0235165.		0
77	Title is missing!. , 2020, 15, e0235165.		0
78	Title is missing!. , 2020, 15, e0235165.		0
79	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
80	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
81	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
82	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0